PL3218378T3 - Pochodne 6-amino-7-bicyklo-7-deazapuryny jako inhibitory kinaz białkowych - Google Patents
Pochodne 6-amino-7-bicyklo-7-deazapuryny jako inhibitory kinaz białkowychInfo
- Publication number
- PL3218378T3 PL3218378T3 PL15793834T PL15793834T PL3218378T3 PL 3218378 T3 PL3218378 T3 PL 3218378T3 PL 15793834 T PL15793834 T PL 15793834T PL 15793834 T PL15793834 T PL 15793834T PL 3218378 T3 PL3218378 T3 PL 3218378T3
- Authority
- PL
- Poland
- Prior art keywords
- deaza
- bicyclo
- amino
- protein kinase
- kinase inhibitors
- Prior art date
Links
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
- 229940083251 peripheral vasodilators purine derivative Drugs 0.000 title 1
- 239000003909 protein kinase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14193197 | 2014-11-14 | ||
| PCT/EP2015/076411 WO2016075224A1 (en) | 2014-11-14 | 2015-11-12 | 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors |
| EP15793834.1A EP3218378B1 (en) | 2014-11-14 | 2015-11-12 | 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3218378T3 true PL3218378T3 (pl) | 2020-10-19 |
Family
ID=51904767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15793834T PL3218378T3 (pl) | 2014-11-14 | 2015-11-12 | Pochodne 6-amino-7-bicyklo-7-deazapuryny jako inhibitory kinaz białkowych |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10221181B2 (pl) |
| EP (1) | EP3218378B1 (pl) |
| JP (1) | JP6421241B2 (pl) |
| KR (1) | KR102562866B1 (pl) |
| CN (1) | CN107108631B (pl) |
| AU (1) | AU2015345054B2 (pl) |
| CA (1) | CA2967125C (pl) |
| CL (1) | CL2017001204A1 (pl) |
| EA (1) | EA039885B1 (pl) |
| ES (1) | ES2792036T3 (pl) |
| MX (1) | MX382607B (pl) |
| PL (1) | PL3218378T3 (pl) |
| WO (1) | WO2016075224A1 (pl) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| WO2016127074A1 (en) | 2015-02-06 | 2016-08-11 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors |
| PT3322706T (pt) | 2015-07-16 | 2021-03-08 | Array Biopharma Inc | Compostos de pirazolo[1,5-a]piridina substituídos como inibidores da quinase do ret |
| TN2019000271A1 (en) | 2015-10-26 | 2021-01-07 | Univ Colorado Regents | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| EP3371171B1 (en) | 2015-11-02 | 2023-10-25 | Blueprint Medicines Corporation | Inhibitors of ret |
| WO2017161269A1 (en) | 2016-03-17 | 2017-09-21 | Blueprint Medicines Corporation | Inhibitors of ret receptor tyrosine kinases |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| TN2019000332A1 (en) | 2016-04-04 | 2021-05-07 | Loxo Oncology Inc | Methods of treating pediatric cancers |
| IL304018A (en) | 2016-04-04 | 2023-08-01 | Loxo Oncology Inc | Liquid formulations of (S)-N-(5-((R)-2-(5,2-difluorophenyl)-pyrrolidine-1-yl)-pyrazolo[5,1-A]pyrimidin-3-yl)-3 -hydroxypyrrolidine-1-carboxamide |
| IL297192A (en) * | 2016-04-15 | 2022-12-01 | Cancer Research Tech Ltd | Heterocyclic compounds as ret kinase inhibitors |
| SMT202200348T1 (it) | 2016-04-15 | 2022-11-18 | Cancer Research Tech Ltd | Composti eterociclici come inibitori della chinasi ret |
| ES2952056T3 (es) | 2016-05-18 | 2023-10-26 | Loxo Oncology Inc | Preparación de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida |
| US10227329B2 (en) | 2016-07-22 | 2019-03-12 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| JP6888101B2 (ja) | 2017-01-18 | 2021-06-16 | アレイ バイオファーマ インコーポレイテッド | ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピラジン化合物 |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| GB201705971D0 (en) | 2017-04-13 | 2017-05-31 | Cancer Res Tech Ltd | Inhibitor compounds |
| JP7110232B2 (ja) | 2017-04-18 | 2022-08-01 | イーライ リリー アンド カンパニー | フェニル－２－ヒドロキシ－アセチルアミノ－２－メチル－フェニル化合物 |
| JP2020519672A (ja) | 2017-05-15 | 2020-07-02 | ブループリント メディシンズ コーポレイション | ＲＥＴ阻害剤とｍＴＯＲＣ１阻害剤との組合せ及び異常なＲＥＴ活性によって媒介されるがんを処置するためのその使用 |
| ES2968421T3 (es) | 2017-06-23 | 2024-05-09 | San Diego State Univ Research Foundation | Atropisomerismo para la selectividad potenciada de inhibidor de cinasa |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| TWI876442B (zh) | 2017-10-10 | 2025-03-11 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| WO2019143977A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| WO2019143991A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS |
| JP6997876B2 (ja) | 2018-01-18 | 2022-02-04 | アレイ バイオファーマ インコーポレイテッド | Ｒｅｔキナーゼ阻害剤としての置換ピラゾリル［４，３－ｃ］ピリジン化合物 |
| BR112020020273A2 (pt) | 2018-04-03 | 2021-04-06 | Blueprint Medicines Corporation | Inibidor de ret para uso no tratamento de câncer tendo uma alteração de ret |
| JP7286755B2 (ja) | 2018-07-31 | 2023-06-05 | ロクソ オンコロジー， インコーポレイテッド | （ｓ）－５－アミノ－３－（４－（（５－フルオロ－２－メトキシベンズアミド）メチル）フェニル）－１－（１，１，１－トリフルオロプロパン－２－イル）－１ｈ－ピラゾール－４－カルボキサミドの噴霧乾燥分散体および製剤 |
| CA3111984A1 (en) * | 2018-09-10 | 2020-03-19 | Array Biopharma Inc. | Fused heterocyclic compounds as ret kinase inhibitors |
| US12172995B2 (en) | 2018-10-24 | 2024-12-24 | Bristol-Myers Squibb Company | Substituted indole and indazole compounds |
| CN111285882B (zh) * | 2018-12-07 | 2022-12-02 | 四川科伦博泰生物医药股份有限公司 | 稠环化合物、包含其的药物组合物及其制备方法和用途 |
| CN113474337A (zh) | 2018-12-19 | 2021-10-01 | 奥瑞生物药品公司 | 作为fgfr抑制剂用于治疗癌症的7-((3，5-二甲氧基苯基)氨基)喹喔啉衍生物 |
| JP2022515198A (ja) | 2018-12-19 | 2022-02-17 | アレイ バイオファーマ インコーポレイテッド | ＦＧＦＲチロシンキナーゼの阻害剤としての置換ピラゾロ［１，５－ａ］ピリジン化合物 |
| US20220348584A1 (en) * | 2019-08-29 | 2022-11-03 | Hibercell, Inc. | Perk inhibiting indolinyl compounds |
| AU2020340427A1 (en) | 2019-08-29 | 2022-03-31 | Hibercell, Inc. | PERK inhibiting compounds |
| WO2021113492A1 (en) | 2019-12-06 | 2021-06-10 | Schrödinger, Inc. | Cyclic compounds and methods of using same |
| MX2022007171A (es) | 2019-12-27 | 2022-08-22 | Schroedinger Inc | Compuestos cíclicos y métodos de uso de estos. |
| DK4146348T3 (da) | 2020-05-08 | 2024-09-30 | Halia Therapeutics Inc | Inhibitorer af nek7-kinase |
| EP4157829A1 (en) | 2020-05-29 | 2023-04-05 | Blueprint Medicines Corporation | Solid forms of pralsetinib |
| CN113214294A (zh) * | 2020-06-10 | 2021-08-06 | 深圳铂立健医药有限公司 | 三环化合物、药物组合物及其应用 |
| CN116490507A (zh) | 2020-09-10 | 2023-07-25 | 薛定谔公司 | 用于治疗癌症的杂环包缩合cdc7激酶抑制剂 |
| CN119454695A (zh) * | 2020-09-23 | 2025-02-18 | 上海润石医药科技有限公司 | Csf1r激酶抑制剂及其用途 |
| US20240148732A1 (en) | 2021-01-26 | 2024-05-09 | Schrödinger, Inc. | Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders |
| TW202300150A (zh) | 2021-03-18 | 2023-01-01 | 美商薛定諤公司 | 環狀化合物及其使用方法 |
| WO2022212326A1 (en) * | 2021-03-29 | 2022-10-06 | Halia Therapeutics, Inc. | Nek7 inhibitors |
| JP2024544632A (ja) | 2021-12-03 | 2024-12-03 | デシフェラ・ファーマシューティカルズ，エルエルシー | Ｇｃｎ２及びｐｅｒｋキナーゼ阻害剤としての複素環式化合物 |
| WO2025059027A1 (en) | 2023-09-11 | 2025-03-20 | Schrödinger, Inc. | Cyclopenta[e]pyrazolo[1,5-a]pyrimidine derivatives as malt1 inhibitors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1112124T5 (da) | 1998-06-17 | 2007-12-27 | Univ Ohio | Elektrostatisk membranudskiller |
| UA80171C2 (en) | 2002-12-19 | 2007-08-27 | Pfizer Prod Inc | Pyrrolopyrimidine derivatives |
| DE602005014964D1 (de) * | 2004-04-02 | 2009-07-30 | Osi Pharm Inc | Mit einem 6,6-bicyclischen ring substituierte heterobicyclische proteinkinaseinhibitoren |
| AU2006316605B2 (en) | 2005-11-17 | 2012-04-26 | Osi Pharmaceuticals, Inc. | Fused bicyclic mTOR inhibitors |
| WO2007106503A2 (en) | 2006-03-13 | 2007-09-20 | Osi Pharmaceuticals, Inc. | Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors |
| GB0605120D0 (en) | 2006-03-14 | 2006-04-26 | Novartis Ag | Organic Compounds |
| GB0725103D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Novel compounds |
| US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
| MX2011000216A (es) * | 2008-07-08 | 2011-03-29 | Intellikine Inc | Inhibidores de cinasa y metodos para su uso. |
| NZ700583A (en) | 2009-04-22 | 2016-04-29 | Acad Of Science Czech Republic | Novel 7-deazapurine nucleosides for therapeutic uses |
| EP2485731B1 (en) | 2009-10-06 | 2016-05-11 | Millennium Pharmaceuticals, Inc. | Heterocyclic compounds useful as pdk1 inhibitors |
| UY33288A (es) | 2010-03-25 | 2011-10-31 | Glaxosmithkline Llc | Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico |
| CN105732639A (zh) | 2012-06-29 | 2016-07-06 | 辉瑞大药厂 | 作为LRRK2抑制剂的4-(取代的氨基)-7H-吡咯并〔2,3-d〕嘧啶类 |
| US9604980B2 (en) | 2012-11-07 | 2017-03-28 | Nerviano Medical Sciences S.R.L. | Substituted pyrimidinyl and pyridinyl-pyrrolopyridinones, process for their preparation and their use as kinase inhibitors |
-
2015
- 2015-11-12 CA CA2967125A patent/CA2967125C/en active Active
- 2015-11-12 KR KR1020177016404A patent/KR102562866B1/ko active Active
- 2015-11-12 CN CN201580061510.2A patent/CN107108631B/zh active Active
- 2015-11-12 WO PCT/EP2015/076411 patent/WO2016075224A1/en not_active Ceased
- 2015-11-12 US US15/526,642 patent/US10221181B2/en active Active
- 2015-11-12 MX MX2017006366A patent/MX382607B/es unknown
- 2015-11-12 AU AU2015345054A patent/AU2015345054B2/en active Active
- 2015-11-12 PL PL15793834T patent/PL3218378T3/pl unknown
- 2015-11-12 ES ES15793834T patent/ES2792036T3/es active Active
- 2015-11-12 EP EP15793834.1A patent/EP3218378B1/en active Active
- 2015-11-12 JP JP2017525822A patent/JP6421241B2/ja active Active
- 2015-11-12 EA EA201791018A patent/EA039885B1/ru unknown
-
2017
- 2017-05-11 CL CL2017001204A patent/CL2017001204A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2967125C (en) | 2022-10-25 |
| MX382607B (es) | 2025-03-13 |
| EA201791018A1 (ru) | 2018-03-30 |
| EP3218378A1 (en) | 2017-09-20 |
| KR102562866B1 (ko) | 2023-08-04 |
| CN107108631B (zh) | 2020-06-16 |
| EA039885B1 (ru) | 2022-03-23 |
| CL2017001204A1 (es) | 2017-12-29 |
| AU2015345054A1 (en) | 2017-06-29 |
| US10221181B2 (en) | 2019-03-05 |
| MX2017006366A (es) | 2018-02-01 |
| AU2015345054B2 (en) | 2020-03-05 |
| CA2967125A1 (en) | 2016-05-19 |
| JP6421241B2 (ja) | 2018-11-07 |
| EP3218378B1 (en) | 2020-01-08 |
| CN107108631A (zh) | 2017-08-29 |
| JP2017533932A (ja) | 2017-11-16 |
| KR20170082637A (ko) | 2017-07-14 |
| ES2792036T3 (es) | 2020-11-06 |
| US20170327506A1 (en) | 2017-11-16 |
| WO2016075224A1 (en) | 2016-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3218378T3 (pl) | Pochodne 6-amino-7-bicyklo-7-deazapuryny jako inhibitory kinaz białkowych | |
| ZA201700115B (en) | Aminopyridazinone compounds as protein kinase inhibitors | |
| IL268614A (en) | Aminotriazolopyridines as kinase inhibitors | |
| EP3149008B8 (en) | Certain protein kinase inhibitors | |
| EP3131900A4 (en) | Heterocyclic kinase inhibitors | |
| IL246785A0 (en) | Benzimidazole-2-amines as midh1 inhibitors | |
| IL246140A0 (en) | History of bicyclic heterocyclics as bromodomain repressors | |
| PL3704118T3 (pl) | Aminotriazolopirydazyny jako inhibitory kinaz | |
| SG11201610770PA (en) | Quinolizinone derivatives as pi3k inhibitors | |
| ZA201808014B (en) | Adenine derivatives as protein kinase inhibitors | |
| ZA201808238B (en) | Certain protein kinase inhibitors | |
| IL258438B (en) | 2-Aminoquinoline derivatives as p70s6 kinase inhibitors | |
| EP3186247A4 (en) | Protein kinase inhibitors | |
| IL252866B (en) | History of imidazopyridazine as pi3k beta inhibitors | |
| EP3224248A4 (en) | Certain protein kinase inhibitors | |
| ZA201908372B (en) | Pyridoquinazoline derivatives useful as protein kinase inhibitors | |
| GB201519381D0 (en) | Kinase inhibitors | |
| GB201519382D0 (en) | Kinase inhibitors | |
| AU2014903812A0 (en) | Novel kinase inhibitors i | |
| TH1501006103A (th) | สารยับยั้งโปรตีนไคเนส | |
| AU2015904223A0 (en) | Novel kinase inhibitors i | |
| AU2015903106A0 (en) | Novel kinase inhibitors ii | |
| GB201409661D0 (en) | Novel compounds and their use as kinase inhibitors | |
| GB201405532D0 (en) | Novel compounds and their use as Kinase inhibitors |